Cellphire: Cellphire Announces Exercise by BARDA of Option 3 of Contract to Develop Platelet-Based Hemostatic

ROCKVILLE, Md., April 21, 2020 /PRNewswire/ -- Cellphire, Inc., the global leader in long-term stabilization and storage of platelets, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, has exercised its third contract option valued at $33.3 million to support Cellphire's next generation platelet-based hemostatic product, Thrombosomes®, through a Phase 2 clinical trial in bleeding thrombocytopenic patients. The option was exercised under the company's multi-year contract with BARDA, valued up to $82.6 million, to advance the development of freeze-dried platelets for disaster response....Full story available on Benzinga.com